18F-FDG-PET to Discriminate Biologically Malignant Pancreatic Neuroendocrine Tumors Abstract #1690

Introduction: 18F-FDG-PET is widely used to detect malignant tumors. However, the efficacy for pancreatic neuroendocrine tumors (PNETs) is reported to be limited in the clinical practice.
Aim(s): In this study, we reassessed the clinical significance of detection of PNET by 18F-FDG-PET.
Materials and methods: We retrospectively reviewed patients with PNETs who were treated at Kyoto University Hospital between January 2007 and December 2016. Patient’s backgrounds, clinical course and imaging were collected from the medical records. We compared the findings of images, including 18F-FDG-PET, between patients with or without metastatic diseases.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Asahi Sato

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#2685 Apatinib Inhibits Tumor Growth and Angiogenesis in PNET Models
Introduction: Angiogenesis has a pivotal role in the growth and metastasis of pancreatic neuroendocrine tumors (PNETs). Apatinib inhibits angiogenesis as a highly selective KDR inhibitor and has been used to treat advanced gastric cancer and malignancies in clinical settings. However, the efficacy of apatinib in PNETs remains unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Shan Wu
Authors: Wu S, Zhou J, Guo J, Hua Z, ...
#2689 Correlation between Immunohistochemical Markers Expression and Lymph Node Metastasis in Gastroenteropancreatic Neuroendocrine Neoplasms: A Nation-Wide 10-Year Retrospective Clinical Epidemiological Study in China
Introduction: Previous research on the correlation between different pathological features and the development of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) is rare in China.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Huan Yang
Authors: Yang H, Shi S, Zhang S, Ji Y, ...
#2693 The Distinctive Character of Micro-Vasculature and Immune Cell Infiltration in Cystic Pancreatic Neuroendocrine Tumors
Introduction: Hypervascularity is main character of pancreatic neuroendocrine tumors (PanNETs), cystic PanNET (CPanNET) are unique type of PanNETs for which the microenvironment remains unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Heli Gao
Authors: Gao H, ...
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
Authors: Isiangulova A, Khasanov R, ...